Merck and oncology: A conversation with Dr Gregory Lubiniecki at ASCO 2025

Onsite in Chicago at ASCO 2025, web editor Nicole Raleigh spoke with Dr Gregory Lubiniecki, VP, global clinical development, at Merck.

The conversation explores data presented on the Phase 2 portion of the waveLINE-003 in patients with relapsed/refractory DLBCL, as well as the KEYNOTE-689 trial and information on Phase 1 data on investigational G12C inhibitor MK-1084.

Dr Lubiniecki also discusses KEYTRUDA long-term results and Merck’s position in metastatic and rare cancers.

Watch this and other conversations from ASCO 2025 here.